Clinical trials: Brain Necrosis
Ischemic Stroke
Treatment With Intent to Generate Endovascular Reperfusion
Tigertriever is a CE marked mechanical revascularization device indicated to restore blood flow by removing thrombus from a large intracranial vessel in patients experiencing ischemic stroke within 8 hours of symptom onset.
- Trial name
- TIGER (NCT03474549)
- Testing
- Tigertriever revascularization device
- Where
- 17 sites in United States, Israel
- Volunteers
- 160 people
- Sponsor
- Rapid Medical
Ischemic Stroke
Mexidol® Safety and Efficacy in Treatment of Hyperacute and Acute Ischemic Stroke
The primary objective of this study is to further define the mechanisms of action of Mexidol® (solution for intravenous and intramuscular injection, 50 mg/ml) and Mexidol® FORTE 250 (film-coated tablets, 250 mg) in the hyperacute…
- Trial name
- NCT07575984
- Testing
- Mexidol, Glycine
- Where
- 9 sites in Russia
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Pharmasoft
Stroke
Post-marketing Clinical Study of Alteplase for Acute Ischemic Stroke （Japan Alteplase Clinical Trial Ⅱ：J-ACT Ⅱ）
The purpose of this study is to confirm the efficacy and safety of intravenously administered alteplase in patients with acute ischemic stroke based on the rate of recanalization assessed by magnetic resonance angiography (MRA)…
- Trial name
- NCT00412867
- Testing
- Alteplase
- Where
- Japan
- Volunteers
- 58 people
- Sponsor
- Tanabe Pharma Corporation
Brain Diseases, Cardiovascular Diseases
pRESET for Occlusive Stroke Treatment
Compare the safety and effectiveness of pRESET to Solitaire in the treatment of stroke related to large vessel occlusion
- Conditions
- Brain Diseases, Cardiovascular Diseases, Central Nervous System Diseases, Cerebrovascular Disorders
- Trial name
- PROST (NCT03994822)
- Testing
- Mechanical Thrombectomy using the pRESET Thrombectomy device, Mechanical Thrombectomy using the Solitaire Revascularization Device
- Where
- 24 sites in United States, Germany
- Volunteers
- 340 people
- Sponsor
- phenox Inc.
Tetraplegia/Tetraparesis, Quadriplegia
GB-PRIME: An Early Feasibility Study of a Precise Robotically Implanted Brain-Computer Interface for the Control of External Devices
The GB-PRIME Study is an early feasibility study designed to assess the clinical safety and functionality of the Neuralink N1 Implant and R1 Robot.
- Conditions
- Tetraplegia/Tetraparesis, Quadriplegia, Quadriplegia/Tetraplegia, Cervical Spinal Cord Injury
- Trial name
- GB-PRIME (NCT07127172)
- Testing
- N1 Implant, R1 Robot
- Where
- 2 sites in United Kingdom
- Volunteers
- 7 people
- Sponsor
- Neuralink Corp
Atherosclerosis, Ischemia
Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Patients With Atherosclerosis (TRA 2°P - TIMI 50) (P04737)
The study is designed to determine whether vorapaxar, when added to the existing standard of care (SOC) for preventing heart attack and stroke (eg, aspirin, clopidogrel) in participants with a known history of atherosclerosis…
- Conditions
- Atherosclerosis, Ischemia, Myocardial Infarction, Cerebrovascular Accident
- Trial name
- NCT00526474
- Testing
- Vorapaxar
- Volunteers
- 26,449 people
- Sponsor
- Merck Sharp & Dohme LLC
Prevention & Control
Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease
The primary objectives of this study are: To determine whether rivaroxaban 2.5 mg twice daily (bid) + aspirin 100 mg once daily (od) compared with aspirin 100 mg od reduces the risk of a composite of myocardial infarction…
- Trial name
- COMPASS (NCT01776424)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Aspirin, Pantoprazole
- Where
- 565 sites in United States, Argentina and 31 more
- Volunteers
- 27,395 people
- Sponsor
- Bayer
Heart Attack, Stroke
ACS Registry - A Non-interventional Study to Estimate the Rates of Outcomes in ACS Patients in Moscow
Cardiovascular diseases (CVD) are currently the leading cause of death in industrialized countries and are expected to become the leading cause of death in emerging countries by 20201.
- Conditions
- Heart Attack, Stroke, Cardiovascular Death
- Trial name
- NCT03654157
- Where
- 27 sites in Russia
- Volunteers
- 1,576 people
- Sponsor
- AstraZeneca
Stroke, Motor Activity
Observational Study of Ischaemic Stroke
The rationale for this study is to facilitate future Phase II/III clinical trials and improve outcome for patients suffering residual disability after an ischaemic stroke.
- Trial name
- OSIS (NCT01859572)
- Where
- United Kingdom
- Volunteers
- 110 people
- Sponsor
- ReNeuron Limited
Ischemic Symptoms, Cerebral Infarction
Pletaal SR Post Marketing Observational Study
This is a Post Marketing Observational Study of cilostazol (Pletaal® SR capsule). As this study is observational in nature to collect the safety data after administrating the Pletaal SR capsule, from baseline to 16 weeks.
- Trial name
- PLTSRPMOS (NCT01782833)
- Testing
- This is Non-interventional study
- Where
- 4 sites in South Korea
- Volunteers
- 3,635 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Ischemic Stroke, Chronic Stroke
Investigation of Neural Stem Cells in Ischemic Stroke
A study of stereotactic, intracerebral injection of CTX0E03 neural stem cells into patients with moderate to moderately severe disability as a result of an ischemic stroke.
- Conditions
- Ischemic Stroke, Chronic Stroke, Hemiparesis, Arm Paralysis
- Trial name
- PISCES III (NCT03629275)
- Testing
- CTX0E03 Drug Product and delivery device
- Where
- 23 sites in United States
- Volunteers
- 15 people
- Sponsor
- ReNeuron Limited
Hemorrhage, Gastrointestinal, Myocardial Infarction
A Study of Channeling in the Use of Nonprescription Paracetamol and Ibuprofen in an Electronic Medical Records Database: Evidence and Implications
The Purpose of this study is to examine whether evidence of channeling exists by analyzing within a cohort of participants with first prescriptions of single-ingredient paracetamol or ibuprofen (or both) whether participants with…
- Conditions
- Hemorrhage, Gastrointestinal, Myocardial Infarction, Stroke, Kidney Diseases
- Trial name
- NCT02830178
- Where
- United States
- Volunteers
- 144,337 people
- Sponsor
- Janssen Research & Development, LLC
ST Elevation Myocardial Infarction
Study of Efficacy and Safety of GNR-060 vs Metalyse in Patients With ST Elevation Myocardial Infarction
GNR-060(JSC "GENERIUM", Russia) is a proposed biosimilar to the referent product Metalyse. This study is to compare the clinical efficacy and safety of GNR-060 vs Metalyse as a thrombolitic agent in patients with with ST…
- Trial name
- NCT05601999
- Testing
- GNR-060, Metalyse
- Where
- 11 sites in Russia
- Volunteers
- 244 people
- Sponsor
- AO GENERIUM
Thrombosis, Stent Thrombosis
Evaluating Pharmacogenomic Variants for Cardiology Therapeutics
Cipherome's Lighthouse is a clinical decision support tool that incorporates a patient's pharmacogenetic information to determine therapeutic strategy, including determining appropriate dosage or assessing the likelihood of…
- Conditions
- Thrombosis, Stent Thrombosis, Bleeding, Myocardial Infarction
- Trial name
- CARES2 (NCT04702113)
- Testing
- Cipherome Lighthouse Pilot
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Cipherome, Inc.
Alzheimer Disease, Dementia
An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease
The goal of this Phase 2 Open Label study is to evaluate long-term safety, tolerability, and efficacy of XPro1595 on measures of cognition, function and brain quality in individuals with Alzheimer's Disease.
- Conditions
- Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases
- Trial name
- NCT05522387
- Testing
- XPro1595
- Where
- 4 sites in Australia
- Volunteers
- 11 people
- Sponsor
- Inmune Bio, Inc.
Systemic Juvenile Idiopathic Arthritis, Hereditary Periodic Fevers
A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 Studies
The objective of this extension protocol is to collect safety data (serious and non-serious adverse events) and to provide continuous canakinumab to patients in France who completed study CACZ885G2301E1(NCT00891046), CACZ885G2306…
- Trial name
- NCT02334748
- Testing
- canakinumab
- Where
- 3 sites in France
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
Cardiovascular Disease
The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
This study evaluates the PCSK9 inhibitor, Bococizumab (PF-04950615;RN316), compared to placebo, in reducing the occurrrence of major cardiovascular events, including cardiovascular death, myocardial infarction, stroke, and…
- Trial name
- SPIRE-2 (NCT01975389)
- Testing
- bococizumab (PF-04950615)
- Where
- 1,595 sites in United States, Argentina and 33 more
- Volunteers
- 10,564 people
- Sponsor
- Pfizer
Stroke, Stroke, Acute Ischemic
NeuroAiD Patient-Reported Outcomes in Patients With Mild to Moderate Ischemic Stroke
This is a randomized, controlled, open-label study of MLC901 (NeuroAiD™ II) in patients with mild to moderate ischemic stroke. Eligible participants will be randomized in a 1:1 ratio to receive MLC901 in combination with standard…
- Conditions
- Stroke, Stroke, Acute Ischemic, Stroke, Ischemic, Stroke, Cryptogenic
- Trial name
- NAiD-PRO (NCT07828210)
- Testing
- MLC901, Standard treatment for acute ischemic stroke
- Where
- Vietnam
- Volunteers
- 80 people
- Sponsor
- EVD Pharmacy and Medical Company Limited
Cardiovascular Disease
Comprehensive Rimonabant Evaluation Study of Cardiovascular ENDpoints and Outcomes
The primary objective is to show whether rimonabant reduces the risk of a heart attack (MI), stroke, or death from an MI or stroke in patients with abdominal obesity with other cardiovascular (CV) risk factors.
- Trial name
- CRESCENDO (NCT00263042)
- Testing
- Rimonabant
- Where
- 43 sites in United States, Argentina and 41 more
- Volunteers
- 18,695 people
- Sponsor
- Sanofi
Cerebral Infarction
Evaluation of the Safety and Potential Therapeutic Effects of Cordstem-ST in Patients With Cerebral Infarction
The objective of the study is to evaluate the safety and the potential therapeutic effects per dose of Cordstem-ST Intravenous Transplantation in Cerebral Infarction subjects
- Trial name
- NCT02378974
- Testing
- Cordstem-ST
- Where
- South Korea
- Volunteers
- 18 people
- Sponsor
- CHABiotech CO., Ltd